Pulse Biosciences Showcases nPulse Cardiac Catheter at AF Symposium with Key Data
Event summary
- Pulse Biosciences will present 6-month and 12-month follow-up data from its Cardiac Catheter Human Feasibility Study in Europe at the AF Symposium.
- The nPulse Cardiac Catheter integrated with Abbott’s EnSiteX™ 3D Mapping System will be featured in a live case transmission on February 7th.
- Preclinical study shows nanosecond pulsed electric fields produce significantly deeper cardiac lesions compared to microsecond pulses.
The big picture
Pulse Biosciences is positioning its nPulse technology as a non-thermal alternative to traditional cardiac ablation methods, aiming to improve treatment outcomes for atrial fibrillation. The integration with Abbott’s EnSiteX™ 3D Mapping System highlights the company’s strategy to leverage existing infrastructure in the electrophysiology space. Success here could accelerate adoption in a market dominated by thermal ablation technologies.
What we're watching
- Clinical Validation
- How the 6- and 12-month follow-up data will influence regulatory approvals and market adoption.
- Technology Integration
- The pace at which Abbott’s EnSiteX™ 3D Mapping System integration enhances workflow efficiency for atrial fibrillation treatments.
- Market Differentiation
- Whether nanosecond PFA technology can sustain its disruptive potential in the competitive cardiac ablation market.
Related topics